In a cross-sectional study of 650 participants (149 with Alzheimer's Disease (AD), 276 with cerebral small vessel disease, and 225 cognitively unimpaired controls), OCTA found distinct ocular microvascular patterns: CSVD showed a higher burden of retinal ischemic perivascular lesions than AD, supporting disease-specific retinal biomarkers. The study also found that while both conditions involve vascular dysfunction, their retinal signatures differ in ways that may help clinicians separate neurodegenerative from cerebrovascular pathology non-invasively.

Why It Matters To Your Practice

• Retinal imaging may offer a practical, non-invasive window into brain microvascular and neurodegenerative disease.

• Distinct OCTA patterns could help clinicians differentiate AD from CSVD when cognitive impairment has mixed or unclear drivers.

• This is especially relevant in older adults, where cerebrovascular disease and dementia pathology often overlap.

Clinical Implications

• A higher retinal ischemic perivascular lesion burden may point more toward CSVD than AD.

• OCTA-derived measures could eventually complement cognitive testing, MRI, and vascular risk assessment in diagnostic workups.

• These findings are hypothesis-generating and not yet ready to replace established diagnostic pathways.

Insights

• The study included 650 participants and compared AD, CSVD, and cognitively unimpaired groups.

• Researchers used optical coherence tomography angiography to characterize ocular microvascular alterations across groups.

• The authors concluded that AD and CSVD have distinct ocular microvascular profiles, supporting OCTA-derived measures as potential biomarkers.

The Bottom Line

• AD and CSVD may leave different retinal microvascular fingerprints on OCTA.

• For clinicians, the near-term value is better understanding of how eye-based biomarkers could refine dementia and vascular cognitive impairment evaluation.

• For now, OCTA is promising but remains adjunctive pending further validation and prospective study.